Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

PLRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Pliant Therapeutics, Inc.NASDAQ: PLRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 61.8M shares rose 0.9% year over year, in line with the +1.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +13.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.9% toward the trailing-twelve-month pace of +1.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
61.8M+0.7% QoQ
Last fiscal yearDec 2025
61.37M+1.4% YoY
LTMMar 2026
61.49M+1.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.9%——
1 year+1.4%——
3-year CAGR+13.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
61.37M USD
Year-over-year change
+1.4%
4-year CAGR
+14.4%

Weighted Avg Shares (Diluted) vs competitors

How PLRX compares with its peers on the latest reported figures

  • PLRX's LTM Mar 2026 weighted avg shares (diluted) of 61.49M shares is the 6th highest of the 10 companies compared; the peer median is 63.26M shares.
  • Its year-over-year change of +1.3% is the 7th highest of 10, against a peer median of +4.7%.
  • Over three fiscal years its annual growth of +13.5% compares with a peer median of +16.8%.
PLRX Competitors Peer median
Weighted Avg Shares (Diluted) for PLRX and competitors
Company Period LTM YoY 3-year CAGR
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
WHWKWhitehawk Therapeutics IncLTM Mar 202669.18M +155.7%+40.1%
GUTSFractyl Health, Inc. Common StockLTM Mar 202666.33M +37.1%+16.8%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
PLRXPliant Therapeutics, Inc.LTM Mar 202661.49M +1.3%+13.5%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
COYACoya Therapeutics, Inc.LTM Mar 202616.73M +5.9%+18.9%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding PLRX) 63.26M+4.7%+16.8%

Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57M9.69M1.58M00
Cost of Revenue00001.7M
Gross Profit7.57M9.69M1.58M0(1.7M)
Gross Margin100.0%100.0%100.0%——
Research & Development77.55M96.94M127.8M169.31M109.16M
Selling, General & Admin27.56M39.95M57.93M59.06M47.22M
Operating Expenses105.11M136.89M185.73M228.37M148.38M
Depreciation & Amortization1.54M3.68M1.84M2.13M1.7M
EBITDA(95.73M)(118.85M)(158.23M)(205.16M)(145.09M)
EBITDA Margin-1264.2%-1227.1%-10014.4%——
Operating Income(97.54M)(127.2M)(184.15M)(228.37M)(150.07M)
Operating Margin-1288.1%-1313.4%-11654.7%——
Interest Income272K4.67M24.08M21.09M0
Interest Expense0791K1.27M3.02M2.56M
Other Income / Expenses272K3.88M22.81M18.06M729K
Income Before Tax(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Pre-Tax Margin-1284.5%-1273.3%-10211.1%——
Income Tax Expense00000
Net Income(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Net Margin-1284.5%-1273.3%-10211.1%——
EPS (Basic)(2.71)(2.94)(2.75)(3.47)(2.43)
EPS (Diluted)(2.71)(2.94)(2.75)(3.47)(2.43)
Weighted Avg Shares35.85M42.02M58.72M60.54M61.37M
Weighted Avg Shares (Diluted)35.85M42.02M58.72M60.54M61.37M

Pliant Therapeutics, Inc.

NASDAQ:PLRX

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.